The European Patent Office (EPO) has decided that the European patent on mutations in breast and ovarian cancer susceptibility (EP 705903) is to be maintained in amended form.
Related Articles
Drug Watch
No-name heroes can save Europe billions
Senza categoria
The people’s pharmacologist
Senza categoria